🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Please re-Tweet if you agree: Good #caregiving focuses on what people living with #Alzheimers disease or other forms of #dementia can do (rather than what they cannot). Offer encouragement, build confidence, share love. #happiness #kindness #quote

📢The new #website is launching tomorrow! 👏 Our platform was designed to provide the most advanced information, support & resources for those who have memory concerns, their families & healthcare providers. Stay tuned!🚀 #Alzheimers #biomarkers #hubofhow

🎉It's launch day!! 🎉We think our new website will be a game-changer for individuals with #memory concerns, their families, busy clinicians and for ALZpath! So please head over to our website now to see it for yourself & let us know what you think💜 #Alzheimers #biomarkers

📢A recent study evaluating our pTau217 #assay and three pTau181 assays found that the ALZpath assay provides a ‘practical diagnostic opportunity to identify #AlzheimersDisease patients’ #hubofhow #biomarkers aan.com/MSA/Public/Eve…

June is Alzheimer’s & Brain Awareness Month! #GoPurple to raise awareness in honor of the more than 6 million Americans living with Alzheimer’s. Learn more: alz.org/abam. #ENDALZ

At the Alzheimer's Association, diversity, equity and inclusion are vital to our mission. This month, we’re celebrating Alzheimer’s & Brain Awareness Month and #PrideMonth. 🌈🏳️‍⚧️ Thank you to all of our LGBTQ+ champions in the fight to #ENDALZ!

June is Alzheimer’s & Brain Awareness Month. 💜 RETWEET to raise awareness in honor of all those impacted by Alzheimer’s and other dementia. Together, we will #ENDALZ.

📣 Exciting Presentations Utilizing Our ALZpath pTau217 Assay at #AAIC23 ! 🌍 Join us in Amsterdam! 👏 Prominent researchers evaluating biomarkers for Alzheimer’s Disease that have utilized our cutting-edge pTau217 assay will present their important findings

#ALZpath #Announces #New #Funding from the #Alzheimer's #Drug #Discovery #Foundation (#ADDF) to #Advance a #Novel, #Diagnostic #Blood-Based #Assay rb.gy/sz2j1 ALZpath

Today📢 ALZpath received Alzheimer's Drug Discovery Foundation funding, backed by Bill Gates, Jeff Bezos and Leonard Lauder, to expand availability and clinical development of ALZPathDx, our highly sensitive blood assay to detect #AlzheimersDisease , even at early stages. alzpath.bio/addf-press-rel…

Jacob Hunter has been appointed as Chief Business Officer at #ALZpath! With 15+ years of biotech & diagnostic business development experience, Jake's expertise will propel us forward in developing innovative Alzheimer's diagnostic solutions! #Leadership

Research affirms high diagnostic accuracy of blood test for Alzheimer’s ALZpath’s pTau217 test could be as accurate as invasive spinal tap, new study suggests. #diagnostics #research #bloodtest #alzheimers #pTau217 longevity.technology/news/research-…

Congratulations to ALZpath - Best Invention of 2024 Award for their #Alzheimers p-tau217 blood test! Patients and physicians benefit as #AlzheimersDisease can be diagnosed more simply. We partnered with ALZpath to use their p-tau217 test in our recent Phase 2 AD Trial.

In this episode, hear from Dr. Lee Honigberg, VP of Research & Development, ALZpath, a provider of diagnostic tools for Alzheimer’s disease. Listen now at buff.ly/4gW23ji 🎙️

🌟MEET OUR FINALISTS🌟 ADVANCEMENTS IN NEUROLOGICAL TREATMENTS 🔹ALZpath pTau217 Antibody - ALZpath 🔹BrainProbe - National Yang Ming Chiao Tung University 國立陽明交通大學 🔹VORANIGO® (vorasidenib tablets) - Servier #EdisonAwards #HealthTech #Biotech #PatientOutcomes #Innovation

Congratulations to our partners ALZpath, one of the Diagnostics Accelerator portfolio companies recognized as one of Fast Company's Most Innovative Biotech Companies of 2025! Their blood test is revolutionizing Alzheimer's care and research. bit.ly/4bIcRR4

Innovation drives the field forward. Great to see Fast Company recognize the innovation and technology @Alzpath, one of the Diagnostics Accelerator portfolio companies as one of the Most Innovative Biotech Companies of 2025!

ALZpath is headed to Toronto for #AAIC25! If you’re attending and want to discuss pTau217 testing or Alzheimer’s diagnostics, we’d love to connect. Reach out to [email protected] to set up a meeting. #AlzheimersDisease #AAIC25 #pTau217 #Diagnostics #ALZpath

#Global #Momentum and #Validation #Grows at #AAIC for #ALZpath #Proprietary pTau217 #Antibody #Use in #Alzheimer's #Disease #Research, #Diagnosis, and #Treatment tinyurl.com/38pjbc4x ALZpath

🗣🎙We also had an interview today with Mike Banville, of ALZpath, who highlighted the company's presentations on its pTau217 antibody at #AAIC25! 🇨🇦 📹 Alzheimer's Association